Elanco Animal Health (NYSE:ELAN – Get Rating) had its price objective trimmed by Stifel Nicolaus from $30.00 to $22.00 in a report released on Friday morning, The Fly reports.
Several other equities research analysts have also recently commented on ELAN. The Goldman Sachs Group dropped their price target on shares of Elanco Animal Health from $37.00 to $32.00 and set a buy rating on the stock in a research report on Thursday, May 19th. Barclays boosted their price target on shares of Elanco Animal Health from $30.00 to $32.00 and gave the stock an equal weight rating in a research report on Monday, February 28th. Finally, Morgan Stanley cut their price objective on Elanco Animal Health to $37.00 and set an overweight rating on the stock in a report on Tuesday, May 17th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $32.20.
ELAN stock opened at $20.61 on Friday. The company has a market capitalization of $9.77 billion, a P/E ratio of -27.85, a PEG ratio of 0.98 and a beta of 0.74. The company has a 50-day simple moving average of $23.39 and a 200 day simple moving average of $25.71. Elanco Animal Health has a fifty-two week low of $19.56 and a fifty-two week high of $37.49. The company has a quick ratio of 1.41, a current ratio of 2.44 and a debt-to-equity ratio of 0.80.
Elanco Animal Health (NYSE:ELAN – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.35 by $0.01. Elanco Animal Health had a negative net margin of 7.65% and a positive return on equity of 6.61%. The firm had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.22 billion. During the same period in the previous year, the business earned $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was down 1.4% compared to the same quarter last year. Equities analysts anticipate that Elanco Animal Health will post 1.17 EPS for the current year.
In other Elanco Animal Health news, Director R David Hoover bought 10,000 shares of the company’s stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $23.33 per share, for a total transaction of $233,300.00. Following the acquisition, the director now directly owns 125,000 shares of the company’s stock, valued at $2,916,250. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.40% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Herold Advisors Inc. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at about $26,000. Tcwp LLC bought a new stake in shares of Elanco Animal Health in the 1st quarter valued at approximately $29,000. CKW Financial Group bought a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $30,000. IndexIQ Advisors LLC bought a new stake in shares of Elanco Animal Health in the 1st quarter valued at approximately $32,000. Finally, Benjamin Edwards Inc. grew its stake in shares of Elanco Animal Health by 157.1% in the 4th quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company’s stock valued at $40,000 after buying an additional 872 shares in the last quarter.
About Elanco Animal Health (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Read More
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
